Table 3.
SNP | Position | Chr | Nearest gene | Reference allele |
Associated phenotype |
Min Cond FDR |
IFGC phase I p-value |
IFGC phase I OR (95% CI) |
IFGC phase II p-value |
IFGC phase II OR (95% CI) |
Meta-analysis p-value |
Meta-analysis OR (95% CI) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
rs4417745 | 241 225 364 | 2 | Intergenic; OTOS | A | PD | 2.73E-02 | 2.52E-05 | 1.36 (1.18-1.57) | 0.47 | 1.06 (0.90-1.25) | 3.20E-04 | 1.22 (1.09-1.36) |
rs7664889 | 77 087 704 | 4 | Intronic; SCARB2 | T | PD | 3.23E-02 | 1.75E-04 | 0.73 (0.62-0.86) | 0.82 | 0.98 (0.81-1.18) | 3.18E-03 | 0.83 (0.73-0.94) |
rs676768 | 116 030 773 | 10 | Intronic; VWA2# | T | PD | 4.25E-02 | 3.12E-04 | 0.78 (0.68-0.90) | 0.55 | 0.96 (0.82-1.11) | 2.40E-03 | 0.86 (0.78-0.95) |
rs1328032 | 71 420 424 | 13 | Intergenic; DACH1 | A | AD | 1.38E-02 | 1.93E-07 | 0.67 (0.57-0.78) | 0.34 | 0.94 (0.83-1.06) | 7.39E-05 | 0.80 (0.72-0.88) |
rs2446406 | 51 679 783 | 15 | Intronic; GLDN# | A | PD | 2.59E-02 | 7.18E-07 | 0.81 (0.74-0.88) | 0.40 | 0.96 (0.87-1.06) | 2.24E-05 | 0.87 (0.82-0.93) |
rs7184882 | 73 737 373 | 16 | In orf; LOC101927998 |
T | AD | 4.24E-02 | 6.64E-07 | 0.71 (0.62-0.81) | 0.08 | 0.89 (0.78-1.02) | 3.08E-06 | 0.78 (0.71-0.86) |
rs199528 | 44 843 136 | 17 | Intronic; WNT3 | T | PD | 1.79E-02 | 4.09E-05 | 0.82 (0.74-0.90) | 0.03 | 0.89 (0.80-0.99) | 9.59E-06 | 0.85 (0.79-0.91) |
rs1358071 | 43 803 189 | 17 | Intronic; CRHR1 | A | PD | 2.01 E-02 | 4.96E-05 | 1.22 (1.12-1.31) | 0.001 | 1.16 (1.07-1.26) | 4.91 E-07 | 1.19 (1.11-1.27) |
rs12964543 | 56 543 095 | 18 | Intronic; ZNF532# | A | PD | 2.71 E-02 | 1.12E-04 | 1.24 (1.11-1.38) | 0.24 | 1.05 (0.96-1.15) | 9.10E-04 | 1.12 (1.05-1.2) |
rs6857 | 45 392 254 | 19 | 3′-UTR; PVRL2# | T | PD | 4.69E-02 | 7.03E-07 | 1.31 (1.18-1.46) | 4.46E-07 | 1.37 (1.21-1.55) | 2.21E-12 | 1.34 (1.23-1.45) |
rs405509 | 45 408 836 | 19 | Intergenic; APOE | T | AD | 5.26E-03 | 1.25E-05 | 1.18 (1.09-1.27) | 0.93 | 1.0 (0.92-1.09) | 5.98E-05 | 1.15 (1.08-1.24) |
ORs provided for the reference allele.
rs676768 not available, proxy SNP rs12782946 from IFGC phase II.
rs2446406 not available, proxy SNP rs2445742 from IFGC phase II.
rs12964543 not available, proxy SNP exm2272683 from IFGC phase II.
rs6857 not available, proxy SNP rs2075650 from IFGC phase II.
AD, Alzheimer's disease; FDR, false discovery rate; FTD, frontotemporal dementia; IFGC, International FTD-Genomics Consortium; PD, Parkinson's disease.